Henry Schein, Inc. (HSIC) Q2 2025 Earnings Call Transcript

Henry Schein (HSIC) reported Q2 2025 global sales of $3.2 billion (+3.3%), but non-GAAP operating margin compressed 79 basis points to 6.96% and non-GAAP EPS declined to $1.10, primarily due to lower U.S. distribution gross margins from glove pricing and targeted sales initiatives. Despite this, the company affirmed its full-year guidance, expecting a stronger second half driven by a rebound in dental equipment and continued momentum in its high-growth Specialty Products and Technology segments. HSIC is initiating new value creation projects with KKR's Capstone and consulting firms to enhance gross margins and efficiencies, with benefits expected from early 2026, complementing over $100 million in restructuring savings by year-end. CEO Stanley Bergman will retire at year-end, transitioning to Chairman, with a successor search underway.

Analysis

Henry Schein's Q2 2025 results present a narrative of strategic margin compression offsetting solid top-line and high-growth segment performance. While global sales grew 3.3% to $3.2 billion, non-GAAP operating margin contracted by 79 basis points to 6.96%, primarily driven by lower gross margins in the U.S. Distribution business. Management attributed this pressure to reduced glove pricing and deliberate, short-term sales initiatives designed to regain market share, noting a return to normal promotional activity and strong sales momentum in July. This weakness in U.S. Dental, where merchandise sales fell 1.2% and equipment sales dropped 4.7% amid tariff uncertainty, was contrasted by strength in the U.S. Medical business (+6.3%), International Dental Equipment (+9.1% constant currency), and robust performance in higher-margin segments. The Technology group's sales accelerated 6.6% in constant currency, driven by a 20% year-over-year increase in cloud-based customers, while the Specialty Products group grew 3.3%. Management maintained its full-year 2025 guidance, signaling strong confidence in a second-half weighted recovery supported by a rebound in the equipment backlog and ongoing restructuring savings now expected to exceed a $100 million run rate by year-end. The announcement of new value creation initiatives with KKR's Capstone, targeting gross margin and efficiency gains from 2026, provides a new forward-looking catalyst, while the planned retirement of CEO Stanley Bergman introduces a key leadership transition.

Key Decisions for Investors

• Investors should scrutinize execution in the second half of the year, as the maintained full-year guidance hinges on a significant acceleration in performance, particularly a rebound in U.S. dental equipment sales and a stabilization of distribution gross margins.
• The new value creation initiatives with KKR Capstone represent a potential long-term catalyst; monitor for specific financial targets and progress updates on these programs, which are critical for achieving the goal of high single-digit to low double-digit earnings growth post-2025.
• Closely track the ongoing shift in profit mix, as the growth of high-margin Technology and Specialty businesses, which contributed 45% of non-GAAP operating income, is essential for offsetting margin pressures in the core distribution segment.
• Factor in the pending CEO transition as a key variable, as the successor's ability to maintain strategic continuity and execute on the BOLD+1 plan and new efficiency programs will be pivotal for future value creation.